
    
      Trevo Registry (China) is a prospective, open-label, multi-center study, and it is the first
      Stryker China trial. This trial assesses real world performance of the TrevoÂ® Retriever which
      is intended to restore blood flow in the neurovasculature by removing thrombus in subjects
      experiencing ischemic stroke. Total of 200 subjects among up to 15 sites in China local will
      participate in this trial. The primary endpoint is revascularization status assessment at the
      end of the procedure using the modified TICI score.
    
  